Conceptualising access in the direct-acting antiviral era: An integrated framework to inform research and practice in HCV care for people who inject drugs

被引:34
|
作者
Hoj, Stine Bordier [1 ]
Jacka, Brendan [1 ]
Minoyan, Nanor [1 ,2 ]
Artenie, Andreea Adelina [1 ,2 ]
Bruneau, Julie [1 ,3 ]
机构
[1] CRCHUM, 900 Rue St Denis,Local R05-746, Montreal, PQ H2X 0A9, Canada
[2] Univ Montreal, Ecole Sante Publ, 7101 Ave Parc, Montreal, PQ H3N 1X9, Canada
[3] Univ Montreal, Fac Med, Dept Med Familiale & Med Urgence, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada
基金
加拿大健康研究院;
关键词
Hepatitis C virus; Treatment; Health services; Injection drug use; Theoretical framework; Ecological framework; HEPATITIS-C VIRUS; PATIENT-REPORTED OUTCOMES; LONG-TERM CONDITIONS; HEALTH-CARE; HIV CARE; UNDERSTANDING BARRIERS; TREATMENT CANDIDACY; BEHAVIORAL-MODEL; UNITED-STATES; SPECIALIST ASSESSMENT;
D O I
10.1016/j.drugpo.2019.04.001
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
As direct-acting antiviral (DAA) therapy costs fall and eligibility criteria are relaxed, people who inject drugs (PWID) will increasingly become eligible for HCV treatment. Yet eligibility does not necessarily equate to access. Amidst efforts to expand treatment uptake in this population, we seek to synthesise and clarify the conceptual underpinnings of access to health care for PWID, with a view to informing research and practice. Integrating dominant frameworks of health service utilisation, care seeking processes, and ecological perspectives on health promotion, we present a comprehensive theoretical framework to understand, investigate and intervene upon barriers and facilitators to HCV care for PWID. Built upon the concept of Candidacy, the framework describes access to care as a continually negotiated product of the alignment between individuals, health professionals, and health systems. Individuals must identify themselves as candidates for services and then work to stake this claim; health professionals serve as gatekeepers, adjudicating asserted candidacies within the context of localised operating conditions; and repeated interactions build experiential knowledge and patient-practitioner relationships, influencing identification and assertion of candidacy over time. These processes occur within a complex social ecology of interdependent individual, service, system, and policy factors, on which other established theories provide guidance. There is a pressing need for a deliberate and nuanced theory of health care access to complement efforts to document the HCV 'cascade of care' among PWID. We offer this framework as an organising device for observational research, intervention, and implementation science to expand access to HCV care in this vulnerable population. Using practical examples from the HCV literature, we demonstrate its utility for specifying research questions and intervention targets across multiple levels of influence; describing and testing plausible effect mechanisms; and identifying potential threats to validity or barrierS to research translation.
引用
收藏
页码:11 / 23
页数:13
相关论文
共 50 条
  • [41] Knowledge of hepatitis C and treatment willingness amongst people who inject drugs in an era of direct acting antivirals
    Mah, Allison
    Hull, Mark W.
    DeBeck, Kora
    Milloy, Michael John
    Dobrer, Sabina
    Nosova, Ekaterina
    Wood, Evan
    Kerr, Thomas
    Hayashi, Kanna
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2017, 47 : 137 - 143
  • [42] Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs
    Scott, N.
    Iser, D.
    Thompson, A.
    Doyle, J.
    Hellard, M.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 90 - 90
  • [43] The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?
    Stone, Jack
    Martin, Natasha K.
    Hickman, Matthew
    Hellard, Margaret
    Scott, Nick
    McBryde, Emma
    Drummer, Heidi
    Vickerman, Peter
    PLOS ONE, 2016, 11 (05):
  • [44] Management of Hepatitis C Virus/HIV Coinfection Among People Who Use Drugs in the Era of Direct-Acting Antiviral-Based Therapy
    Taylor, Lynn E.
    Swan, Tracy
    Matthews, Gail V.
    CLINICAL INFECTIOUS DISEASES, 2013, 57 : S118 - S124
  • [45] In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey
    Yildirim, Figen Sarigul
    User, Ulku
    Sari, Nagehan Didem
    Kurtaran, Behice
    Onlen, Yusuf
    Senates, Ebubekir
    Gunduz, Alper
    Zerdali, Esra
    Karsen, Hasan
    Batirel, Ayse
    Karaali, Ridvan
    Guner, Rahmet
    Yamazhan, Tansu
    Kose, Sukran
    Erben, Nurettin
    Ince, Nevin
    Koksal, Iftihar
    Oztoprak, Nefise Cuvalci
    Yoruk, Gulsen
    Komur, Suheyla
    Bal, Tayibe
    Kaya, Sibel
    Bozkurt, Ilkay
    Gunal, Ozgur
    Yildiz, Ilknur Esen
    Inan, Dilara
    Barut, Sener
    Namiduru, Mustafa
    Tosun, Selma
    Turker, Kamuran
    Sener, Alper
    Hizel, Kenan
    Baykam, Nurcan
    Duygu, Fazilet
    Bodur, Hurrem
    Can, Guray
    Gul, Hanefi Cem
    Tartar, Ayse Sagmak
    Celebi, Guven
    Sunnetcioglu, Mahmut
    Karabay, Oguz
    Karaosmanoglu, Hayat Kumbasar
    Sirmatel, Fatma
    Tabak, Fehmi
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2022, 33 (11): : 971 - 978
  • [46] Hepatitis C Resistance-Associated Substitutions Among People Who Inject Drugs Treated With Direct-Acting Antiviral-Containing Regimens in the PREVAIL Study
    Akiyama, Matthew J.
    Reeves, Jacqueline D.
    Feliciano, Irene
    Lie, Yolanda S.
    Agyemang, Linda
    Litwin, Alain H.
    HEPATOLOGY, 2017, 66 : 478A - 478A
  • [47] Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage study
    Valerio, Heather
    Conway, Anna
    Alavi, Maryam
    Treloar, Carla
    Silk, David
    Murray, Carolyn
    Henderson, Charles
    Amin, Janaki
    Read, Phillip
    Degenhardt, Louisa
    Christmass, Michael
    Montebello, Mark
    Dore, Gregory J.
    Grebely, Jason
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2022, 110
  • [48] Treatment for hepatitis C virus with direct acting antiviral agents: Perspectives and treatment experiences of people who inject drugs
    Karasz, Alison
    Singh, Reena
    Merchant, Krupa
    McKee, M. Diane
    Kim, Arthur Y.
    Page, Kimberly
    Pericot-Valverde, Irene
    Stein, Ellen S.
    Taylor, Lynn E.
    Wagner, Katherine
    Litwin, Alain H.
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2022, 140
  • [49] High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic
    Norton, Brianna L.
    Fleming, Julia
    Bachhuber, Marcus A.
    Steinman, Meredith
    DeLuca, Joseph
    Cunningham, Chinazo O.
    Johnson, Nirah
    Laraque, Fabienne
    Litwin, Alain H.
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2017, 47 : 196 - 201
  • [50] Decentralized, Community-Based Hepatitis C Point-of-Care Testing and Direct-Acting Antiviral Treatment for People Who Inject Drugs and the General Population in Myanmar: Protocol for a Feasibility Study
    Draper, Bridget Louise
    Pedrana, Alisa
    Howell, Jessica
    Yee, Win Lei
    Htay, Hla
    Aung, Khin Sanda
    Shilton, Sonjelle
    Kyi, Khin Pyone
    Naing, Win
    Hellard, Margaret
    JMIR RESEARCH PROTOCOLS, 2020, 9 (07):